For tablet, capsule, granule, and injectable formulation development, memantine hydrochloride pharma-grade API—sometimes transcribed as menantine hydrochloride—is supplied as a white or almost white crystalline powder corresponding to 3,5-dimethyl-1-aminoadamantane hydrochloride, CAS 41100-52-1, molecular formula C12H21N·HCl, and molecular weight 215.76 g/mol. No universal model designation applies; commercial grades are delineated by intended route as oral solid dosage grade and parenteral grade, with route-specific release profiles for particle size, microbial quality, and elemental impurities. The API is released under ICH Q7 GMP conditions with a Type II drug master file or CEP and is specified by the Ph. Eur. and USP monographs for memantine hydrochloride. Representative batch release includes assay by HPLC with an acceptance criterion of 98.0–102.0% on the dried basis, related substances controlled under ICH Q3A thresholds of 0.05% reporting, 0.10% identification, and 0.15% qualification for a daily dose of ≤2 g, loss on drying ≤0.5% by USP <731>, residue on ignition ≤0.1% by USP <281>, residual solvents per ICH Q3C and USP <467>, and elemental impurities per ICH Q3D and USP <232>/<233>. The compound is an uncompetitive NMDA receptor antagonist used in moderate-to-severe Alzheimer disease; finished oral dosage units commonly contain 5–20 mg memantine hydrochloride. Unlike donepezil hydrochloride, galantamine hydrobromide, or rivastigmine, memantine hydrochloride is not an acetylcholinesterase inhibitor and is not directly interchangeable with those agents. Compared with the free base, the hydrochloride salt provides a freely water-soluble crystalline intermediate with reproducible stoichiometry and dissolution behavior. Memantine is achiral; therefore enantiomeric purity is not a release criterion. The oral grade is intended for immediate-release tablets, capsules, and granules; the injectable grade is intended for small-volume parenteral solutions where filtration and endotoxin control are mandatory.

Why Does the Hydrochloride Salt Provide Better Pharmaceutical Processing than the Free Base?

The hydrochloride salt form provides a crystalline, freely water-soluble material with a defined stoichiometric chloride content. Memantine free base exhibits a calculated pKa of 10.27, indicating protonation in the gastric environment; however, salt formation is selected to avoid handling of the neutral amine and to improve blending, dissolution, and batch-to-batch reproducibility. Pharmacopeial solubility classification lists the hydrochloride as freely soluble in water, whereas the free base has lower aqueous solubility. The salt also supports aqueous parenteral compounding without the need for organic co-solvents. Specification of chloride content and assay on the dried basis confirms salt stoichiometry; this distinguishes the pharmaceutical grade from research-grade memantine hydrochloride, which may not be released under ICH Q7 or accompanied by a valid CEP/DMF. The salt form is compatible with direct compression, wet granulation, and extrusion-spheronization processes, provided that the particle size distribution is controlled. Dissolution testing of finished dosage forms is performed by USP <711> using compendial media appropriate for the immediate-release formulation.

Pharmacological differences from other anti-dementia products are material to formulation and clinical use. Memantine hydrochloride is an uncompetitive NMDA receptor antagonist, whereas donepezil hydrochloride and galantamine hydrobromide are acetylcholinesterase inhibitors and rivastigmine is a carbamate inhibitor. This mechanistic distinction means memantine hydrochloride is not titrated on the same cholinergic adverse-effect scale and is not typically associated with cholinergic gastrointestinal effects. For the pharmaceutical manufacturer, the difference matters because memantine hydrochloride API is not interchangeable with those agents in fixed-dose combination tablets; separate compatibility and dissolution testing is required. Unlike rivastigmine, which is chiral, memantine is achiral, so chiral method validation is not required. The oral and injectable grades of memantine hydrochloride therefore differ from other Alzheimer disease APIs both in pharmacology and in release specification requirements.

When memantine hydrochloride is processed into tablet, capsule, and granule dosage forms, particle size distribution and bulk density influence content uniformity, segregation tendency, and downstream flow. In low-dose tablet manufacture, the API is generally pre-blended by geometric dilution or co-milled with microcrystalline cellulose. Production-scale experience on rotary tablet presses indicates that blends with a D90 above 250 µm can segregate in the press hopper, raising content uniformity RSD beyond 3%; lots with D50 between 25 µm and 75 µm and Hausner ratio ≤1.25 are more suitable for direct compression. For wet high-shear granulation in a 600 L bowl granulator, memantine hydrochloride can be added dry or dissolved in the granulating fluid; the solution addition route often improves low-dose distribution but changes granule growth and requires binder adjustment. Capsule filling on dosator and dosing-disc equipment benefits from controlled bulk and tapped density, determined by USP <616>. Granules for oral administration may be prepared by fluid-bed granulation or extrusion-spheronization; the API can partially dissolve during aqueous granulation, so the formulator must verify that recrystallization during drying does not create coarse agglomerates that slow dissolution. Tableted and encapsulated products are tested for dissolution using USP <711> and for blend uniformity using USP <905>.

Batch-to-batch control is maintained by monitoring crystallization parameters, residual solvent profile, and particle size. In oral solid dosage forms, particle size is often more variable than chemical purity; changes in milling configuration or crystallizer shear can shift the D50 by 10–20 µm and alter capsule fill weight or tablet hardness. This is why pharmaceutical grade API is released against route-specific particle size specifications and placed on a control chart during commercial supply. For injectable grade, clean-room handling and low bioburden manufacturing are necessary, and any change in the final crystallization solvent is evaluated under ICH Q3C and ICH Q3D risk assessments. The API manufacturer’s stability data, validation batch records, and analytical method validation reports form part of the regulatory dossier.

Parenteral-Grade Release Requirements for Small-Volume Injectable Formulations

Injectable-grade material is differentiated from oral-grade material by the application of bacterial endotoxin, bioburden, particulate matter, and parenteral elemental impurity controls. The API is not necessarily supplied sterile; the final injectable solution is typically sterilized by filtration through a 0.22 µm membrane filter. Therefore, the API must present a low bioburden and endotoxin profile that allows the finished product to meet its validated limit. Endotoxin testing is conducted by Ph. Eur. 2.6.14 or USP <85>; the limit is derived from the maximum bolus dose and the threshold pyrogenic dose, not from a single universal API specification. A 20 mg memantine dose administered to a 70 kg adult yields a relatively high allowable endotoxin limit by USP <85> calculation, but finished-product manufacturers often adopt stricter internal limits to address batch-to-batch variation and excipient contribution. Injectable formulations generally use memantine hydrochloride dissolved in Water for Injection, with tonicity adjustment and pH control; because the API is in solution, laser diffraction particle size is less relevant than clarity, filter compatibility, and insoluble particulate burden. If the API is supplied as a sterile powder for reconstitution, particle size and reconstitution time become critical, and D90 values ≤20 µm are frequently requested. Elemental impurities are assessed using parenteral PDEs from ICH Q3D and USP <232>/<233>. Residual solvent limits follow ICH Q3C, with special attention to any solvent used in the final crystallization step.

When Direct Compression Favors a Narrow Particle Size Distribution

Direct compression is selected when the API and excipients demonstrate adequate flow and compressibility without granulation. In memantine hydrochloride low-dose formulations, direct compression often requires a narrow particle size distribution because the API is present at unit loads of 5–20 mg and segregation can produce subpotent or superpotent tablets. A D50 between 25 µm and 75 µm and a D90 ≤250 µm are typical targets for oral solid dosage forms, but these values are not compendial limits; they are qualified through process validation and blend uniformity studies using USP <905>. When the API is too coarse, it may remain in the tablet press feed frame and cause assay drift during long runs. When the API is micronized too aggressively, electrostatic charging can reduce flow and increase sticking to punches. In such cases, the formulator may use a 0.5–1.0% colloidal silicon dioxide glidant, and the API may be pre-screened through a 60-mesh sieve. Compaction properties are assessed by compressibility, compactability, and tabletability studies on an instrumented rotary press; ejection force and punch adhesion are monitored because memantine hydrochloride formulations at high compression force can exhibit lamination if the blend is overlubricated with magnesium stearate above 1.5%. These processing boundaries are specific to the finished formulation and are not defined by the API monograph.

Stability of the Hydrochloride Salt Is Governed by Moisture, Temperature, and Packaging Integrity

Bulk memantine hydrochloride should be stored in sealed, low-moisture-barrier packaging; double polyethylene bags inside an aluminum foil laminate or HDPE drum are common. In high-humidity regions, opened containers may show an increase in loss on drying if exposed for extended periods, so sampling should be performed under controlled relative humidity. Long-term storage conditions are assigned according to ICH Q1A(R2) or WHO stability guidance for the relevant climate zone; a retest period is established from real-time data, with accelerated testing at 40°C/75% RH and intermediate testing at 30°C/65% RH where applicable. Solid-state degradation is generally slow; the main stability concerns are moisture uptake and the formation of related substances under thermal stress. In aqueous injectable formulations, pH control, trace metal management, and oxygen exclusion may be required because solution-state degradation can differ from solid-state behavior. The API is not regarded as highly hygroscopic, but packaging and handling should prevent surface moisture accumulation in humid environments. No antioxidant or chelator is required solely for the API; excipient compatibility studies determine the final formulation stability. The product should be protected from strong oxidizing agents and incompatible excipients in the dry state. Data on degradation kinetics in compounded memantine hydrochloride solutions is limited; therefore compatibility with infusion fluids should be confirmed before use.